Incidence of Venous Thromboembolic Events in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Palliative Chemotherapy: A Retrospective Cohort Study
- 1 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 2 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 3 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 4 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 5 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 6 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
- 7 Medical Oncology Department, Hassan II University Hospital, Fez, Morocco
Abstract
Introduction: Pancreatic cancer is strongly associated with venous thromboembolism (VTE), contributing to significant morbidity and mortality. The aim of this study was to determine the incidence of venous thromboembolism (VTE) among patients with metastatic pancreatic adenocarcinoma receiving palliative chemotherapy at the Medical Oncology Department, Hassan II University Hospital, Fez. Methods: Retrospective cohort including 67 patients treated with FOLFIRINOX or gemcitabine from January 2021 to December 2023. Patients with prior VTE or on anticoagulation were excluded. Cumulative incidence of VTE was estimated considering death as a competing risk. Results: Mean age 63.5 years; male-to-female ratio 4:1. Tumors were mainly in the pancreatic head (65%). At follow-up, 46 patients had died, 6 were lost to follow-up, and 15 were alive. VTE occurred in 28 patients (41.8%): isolated DVT 42.9%, isolated PE 35.7%, combined PE + DVT 21.4%. Cumulative incidence was 26.9% at 12 months and 38.8% at 36 months, with most events occurring during the first year. Conclusion: VTE is common and occurs early in patients with metastatic pancreatic adenocarcinoma under palliative chemotherapy, highlighting the need for appropriate prophylactic strategies.
- Arshad, A., Al-Leswas, D., Al-Taan, O., Stephenson, J., Metcalfe, M., Steward, W.P., et al. (2013) Pooled Survival and Response Data from Phase III Randomized Controlled Trials for Gemcitabine-Based Regimes in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology , 36, 411-414. https://doi.org/10.1097/coc.0b013e3182124216
- Imberti, D., Agnelli, G., Ageno, W., Moia, M., Palareti, G., Pistelli, R., et al. (2008) Clinical Characteristics and Management of Cancer-Associated Acute Venous Thromboembolism: Findings from the MASTER Registry. Haematologica , 93, 273-278. https://doi.org/10.3324/haematol.11458
- Key, N.S., Khorana, A.A., Kuderer, N.M., et al. (2020) Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update. Journal of Clinical Oncology , 38, 496-520.
- Sproul, E.E. (1938) Carcinoma and Venous Thrombosis: The Frequency of Association of Carcinoma in the Body or Tail of the Pancreas with Multiple Venous Thrombosis. American Journal of Cancer , 34, 566-585.
- Bergqvist, D., Wåhlander, K., Eriksson, H., Sternby, N. and Ögren, M. (2006) Trousseau’s Syndrome—What Is the Evidence? Thrombosis and Haemostasis , 95, 541-545. https://doi.org/10.1160/th05-10-0694
- Blom, J.W., Vanderschoot, J.P.M., Oostindiër, M.J., Osanto, S., van der Meer, F.J.M. and Rosendaal, F.R. (2006) Incidence of Venous Thrombosis in a Large Cohort of 66 329 Cancer Patients: Results of a Record Linkage Study. Journal of Thrombosis and Haemostasis , 4, 529-535. https://doi.org/10.1111/j.1538-7836.2006.01804.x
- Frere, C., Bournet, B., Gourgou, S., et al. (2020) Incidence of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Cancer and Factors Associated with Outcomes. Gastroenterology , 158, 1346-1358.e4.
- Jeong, H.T., Bae, J.H., Kim, H.G. and Han, J. (2023) Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis. The Korean Journal of Gastroenterology , 81, 109-120. https://doi.org/10.4166/kjg.2022.137
- Farge, D., Frere, C., Connors, J.M., et al. (2022) 2022 International Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Patients with Cancer, Including Patients with COVID-19. The Lancet Oncology , 23, e334-e347.